Medical Information
If you have a medical information question or product quality concern regarding a Daiichi Sankyo product you can contact our Medical Information service on 0800 028 5122 or by email to medinfo-uk@daiichisankyo.com
Please note: Pharmaceutical company Medical Information services cannot provide personal medical advice.
Side Effect Reporting
If, as a patient, you experience any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible side effects not listed in the package leaflet. By reporting side effects you can help provide more information on the safety of our medicines.
Patients and Healthcare Professionals can report side effects directly to the MHRA via the Yellow Card scheme at https://yellowcard.mhra.gov.uk/
Medicines with the inverted black triangle symbol (▼) are subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See https://yellowcard.mhra.gov.uk/ for how to report side effects.
If you are a healthcare professional, side effects (adverse events) should also be reported to Daiichi Sankyo by email at pharmacovigilance_uk@daiichisankyo.com or by phone on 0800 028 5122.
UK Products
| Product | Summary of Product Characteristics (SmPC) | Patient Information Leaflet (PIL) |
|---|---|---|
| Enhertu▼ (trastuzumab deruxtecan) | UK SmPC | UK PIL |
| Lixiana (edoxaban tosilate) | UK SmPC | UK PIL |
| Nilemdo (bempedoic acid) | UK SmPC | UK PIL |
| Nustendi (bempedoic acid, ezetimibe) | UK SmPC | UK PIL |
Olmetec (Discontinued) | UK SmPC | UK PIL |
Olmetec Plus 20 mg/12.5 mg
| UK SmPC | UK PIL |
Olmetec Plus 40 mg/12.5 mg (Discontinued) | UK SmPC | UK PIL |
Sevikar (Discontinued) | UK SmPC | UK PIL |
Sevikar HCT (Discontinued) | UK SmPC | UK PIL |
| Vanflyta ▼ 17.7 mg (quizartinib) | UK SmPC | UK PIL |
| Vanflyta ▼ 26.5 mg (quizartinib) | UK SmPC | UK PIL |
UK/DSC/09/26/0001 - September 2026
